|
1
|
SGO Clinical Practice Endometrial Cancer
Working Group, . Burke WM, Orr J, Leitao M, Salom E, Gehrig P,
Olawaiye AB, Brewer M, Boruta D, Villella J, et al: Endometrial
cancer: A review and current management strategies: Part I. Gynecol
Oncol. 134:385–392. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Liao C, Zhang D, Mungo C, Tompkins DA and
Zeidan AM: Is diabetes mellitus associated with increased incidence
and disease-specific mortality in endometrial cancer? A systematic
review and meta-analysis of cohort studies. Gynecol Oncol.
135:163–171. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Renehan AG, Tyson M, Egger M, Heller RF
and Zwahlen M: Body-mass index and incidence of cancer: A
systematic review and meta-analysis of prospective observational
studies. Lancet. 371:569–578. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sivalingam VN, Myers J, Nicholas S, Balen
AH and Crosbie EJ: Metformin in reproductive health, pregnancy and
gynaecological cancer: Established and emerging indications. Hum
Reprod Update. 20:853–868. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Febbraro T, Lengyel E and Romero IL: Old
drug, new trick: Repurposing metformin for gynecologic cancers?
Gynecol Oncol. 135:614–621. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jang M, Cai L, Udeani GO, Slowing KV,
Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta
RG, et al: Cancer chemopreventive activity of resveratrol, a
natural product derived from grapes. Science. 275:218–220. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pendurthi UR, Williams JT and Rao LV:
Resveratrol, a polyphenolic compound found in wine, inhibits tissue
factor expression in vascular cells: A possible mechanism for the
cardiovascular benefits associated with moderate consumption of
wine. Arterioscler Thromb Vasc Biol. 19:419–426. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baur JA, Pearson KJ, Price NL, Jamieson
HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K,
et al: Resveratrol improves health and survival of mice on a
high-calorie diet. Nature. 444:337–342. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Singh CK, Ndiaye MA and Ahmad N:
Resveratrol and cancer: Challenges for clinical translation.
Biochim Biophys Acta. 1852:1178–1185. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carter LG, D'Orazio JA and Pearson KJ:
Resveratrol and cancer: Focus on in vivo evidence. Endocr Relat
Cancer. 21:R209–R225. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bhat KP and Pezzuto JM: Resveratrol
exhibits cytostatic and antiestrogenic properties with human
endometrial adenocarcinoma (Ishikawa) cells. Cancer Res.
61:6137–6144. 2001.PubMed/NCBI
|
|
12
|
Kaneuchi M, Sasaki M, Tanaka Y, Yamamoto
R, Sakuragi N and Dahiya R: Resveratrol suppresses growth of
Ishikawa cells through down-regulation of EGF. Int J Oncol.
23:1167–1172. 2003.PubMed/NCBI
|
|
13
|
Sexton E, Van Themsche C, LeBlanc K,
Parent S, Lemoine P and Asselin E: Resveratrol interferes with AKT
activity and triggers apoptosis in human uterine cancer cells. Mol
Cancer. 5:452006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gasparrini M, Giampieri F, Alvarez M,
Suarez J, Mazzoni L, Forbes Y, Hernandez T, Quiles LJ, Bullon P and
Battino M: AMPK as a new attractive therapeutic target for disease
prevention: The role of dietary compounds AMPK and Disease
Prevention. Curr Drug Targets. 17:865–889. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Faubert B, Vincent EE, Poffenberger MC and
Jones RG: The AMP-activated protein kinase (AMPK) and cancer: Many
faces of a metabolic regulator. Cancer Lett. 356:165–170. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Umene K, Banno K, Kisu I, Yanokura M,
Nogami Y, Tsuji K, Masuda K, Ueki A, Kobayashi Y, Yamagami W, et
al: New candidate therapeutic agents for endometrial cancer:
Potential for clinical practice (review). Oncol Rep. 29:855–860.
2013.PubMed/NCBI
|
|
17
|
Howitz KT, Bitterman KJ, Cohen HY, Lamming
DW, Lavu S, Wood JG, Zipkin RE, Chung P, Kisielewski A, Zhang LL,
et al: Small molecule activators of sirtuins extend Saccharomyces
cerevisiae lifespan. Nature. 425:191–196. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo J, Nikolaev AY, Imai S, Chen D, Su F,
Shiloh A, Guarente L and Gu W: Negative control of p53 by Sir2alpha
promotes cell survival under stress. Cell. 107:137–148. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Roth M and Chen WY: Sorting out functions
of sirtuins in cancer. Oncogene. 33:1609–1620. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Borriello A, Bencivenga D, Caldarelli I,
Tramontano A, Borgia A, Pirozzi AV, Oliva A and Ragione F Della:
Resveratrol and cancer treatment: Is hormesis a yet unsolved
matter? Curr Pharm Des. 19:5384–5393. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Opipari AW Jr, Tan L, Boitano AE, Sorenson
DR, Aurora A and Liu JR: Resveratrol-induced autophagocytosis in
ovarian cancer cells. Cancer Res. 64:696–703. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Trincheri NF, Follo C, Nicotra G,
Peracchio C, Castino R and Isidoro C: Resveratrol-induced apoptosis
depends on the lipid kinase activity of Vps34 and on the formation
of autophagolysosomes. Carcinogenesis. 29:381–389. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hsu KF, Wu CL, Huang SC, Wu CM, Hsiao JR,
Yo YT, Chen YH, Shiau AL and Chou CY: Cathepsin L mediates
resveratrol-induced autophagy and apoptotic cell death in cervical
cancer cells. Autophagy. 5:451–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Puissant A, Robert G, Fenouille N, Luciano
F, Cassuto JP, Raynaud S and Auberger P: Resveratrol promotes
autophagic cell death in chronic myelogenous leukemia cells via
JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res.
70:1042–1052. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
In K, Park J and Park H: Resveratrol at
high doses acts as an apoptotic inducer in endothelial cells.
Cancer Res Treat. 38:48–53. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mizushima N and Komatsu M: Autophagy:
Renovation of cells and tissues. Cell. 147:728–741. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guo JY, Xia B and White E:
Autophagy-mediated tumor promotion. Cell. 155:1216–1219. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pineda CT, Ramanathan S, Tacer K Fon, Weon
JL, Potts MB, Ou YH, White MA and Potts PR: Degradation of AMPK by
a cancer-specific ubiquitin ligase. Cell. 160:715–728. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Corcelle E, Djerbi N, Mari M, Nebout M,
Fiorini C, Fénichel P, Hofman P, Poujeol P and Mograbi B: Control
of the autophagy maturation step by the MAPK ERK and p38: Lessons
from environmental carcinogens. Autophagy. 3:57–59. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Solomon VR and Lee H: Chloroquine and its
analogs: A new promise of an old drug for effective and safe cancer
therapies. Eur J Pharmacol. 625:220–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
van der Heijden JW, Dijkmans BA, Scheper
RJ and Jansen G: Drug insight: Resistance to methotrexate and other
disease-modifying antirheumatic drugs-from bench to bedside. Nat
Clin Pract Rheumatol. 3:26–34. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lee SJ, Silverman E and Bargman JM: The
role of antimalarial agents in the treatment of SLE and lupus
nephritis. Nat Rev Nephrol. 7:718–729. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Brito-Zeron P, Sisó-Almirall A, Bové A,
Kostov BA and Ramos-Casals M: Primary Sjögren syndrome: An update
on current pharmacotherapy options and future directions. Expert
Opin Pharmacother. 14:279–289. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yang ZJ, Chee CE, Huang S and Sinicrope
FA: The role of autophagy in cancer: Therapeutic implications. Mol
Cancer Ther. 10:1533–1541. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Amaravadi RK, Lippincott-Schwartz J, Yin
XM, Weiss WA, Takebe N, Timmer W, DiPaola RS, Lotze MT and White E:
Principles and current strategies for targeting autophagy for
cancer treatment. Clin Cancer Res. 17:654–666. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Fukuda T, Oda K, Wada-Hiraike O, Sone K,
Inaba K, Ikeda Y, Miyasaka A, Kashiyama T, Tanikawa M, Arimoto T,
et al: The anti-malarial chloroquine suppresses proliferation and
overcomes cisplatin resistance of endometrial cancer cells via
autophagy inhibition. Gynecol Oncol. 137:538–545. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Su D, Cheng Y, Liu M, Liu D, Cui H, Zhang
B, Zhou S, Yang T and Mei Q: Comparison of piceid and resveratrol
in antioxidation and antiproliferation activities in vitro. PLoS
One. 8:e545052013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu ML, Li H, Yu LJ, Chen XY, Kong QY, Song
X, Shu XH and Liu J: Short-term resveratrol exposure causes in
vitro and in vivo growth inhibition and apoptosis of bladder cancer
cells. PLoS One. 9:e898062014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhao XY, Yang S, Chen YR, Li PC, Dou MM
and Zhang J: Resveratrol and arsenic trioxide act synergistically
to kill tumor cells in vitro and in vivo. PLoS One. 9:e989252014.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chen S, Zhou N, Zhang Z, Li W and Zhu W:
Resveratrol induces cell apoptosis in adipocytes via AMPK
activation. Biochem Biophys Res Commun. 457:608–613. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Q, Wang B, Zang W, Wang X, Liu Z, Li
W and Jia J: Resveratrol inhibits the growth of gastric cancer by
inducing G1 phase arrest and senescence in a Sirt1-dependent
manner. PLoS One. 8:e706272013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Samari HR and Seglen PO: Inhibition of
hepatocytic autophagy by adenosine, aminoimidazole-4-carboxamide
riboside, and N6-mercaptopurine riboside. Evidence for involvement
of amp-activated protein kinase. J Biol Chem. 273:23758–23763.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike
O, Kashiyama T, Enomoto A, Hosoya N, Koso T, Fukuda T, Inaba K, et
al: Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase
(PARP) inhibitor, in cultured endometrial carcinoma cells. BMC
Cancer. 14:1792014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Oda K, Ikeda Y, Kawana K, Osuga Y and
Fujii T: mTOR signaling in endometrial cancer: From a molecular and
therapeutic point of view. Curr Obstet Gynecol Rep. 4:1–10. 2015.
View Article : Google Scholar
|
|
45
|
Hung CM, Garcia-Haro L, Sparks CA and
Guertin DA: mTOR-dependent cell survival mechanisms. Cold Spring
Harb Perspect Biol. 4(pii): a0087712012.PubMed/NCBI
|
|
46
|
Li J, Qin Z and Liang Z: The prosurvival
role of autophagy in resveratrol-induced cytotoxicity in human U251
glioma cells. BMC Cancer. 9:2152009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Filippi-Chiela EC, Villodre ES, Zamin LL
and Lenz G: Autophagy interplay with apoptosis and cell cycle
regulation in the growth inhibiting effect of resveratrol in glioma
cells. PLoS One. 6:e208492011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Tang Q, Li G, Wei X, Zhang J, Chiu JF,
Hasenmayer D, Zhang D and Zhang H: Resveratrol-induced apoptosis is
enhanced by inhibition of autophagy in esophageal squamous cell
carcinoma. Cancer Lett. 336:325–337. 2013. View Article : Google Scholar : PubMed/NCBI
|
